Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
Bryan Unger, Director of Business Development at Microvascular Therapeutics, reposted from NuvOx Therapeutics on LinkedIn:
”Proud to share that the first patient has been enrolled in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion.
Stroke is one of the leading drivers of long-term disability and healthcare costs, with lifelong care representing a substantial burden for patients, families, and health systems.
Our Phase IIa data for NanO₂ showed strong potential in reducing this burden.
Reaching the first patient enrolled is a critical milestone.
We are grateful to the clinical teams and partners who are advancing this work.”
Quoting NuvOx Therapeutics‘s post:
”We have enrolled the first patient in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion (LVO).
NOVEL is a multicenter, randomized, placebo-controlled study funded by the NIHR (National Institute for Health and Care Research)–MRC EME Programme, and co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.
This milestone advances NanO₂, designed to rapidly improve tissue oxygenation, toward addressing one of the most severe and costly forms of stroke.
We thank our clinical collaborators and funding partners as we activate additional sites and accelerate enrollment.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH